6月12日电，BioNTech以12.5亿美元收购CureVac以增强癌症业务。

Group 1 - BioNTech has acquired CureVac for $1.25 billion to enhance its cancer business [1] - The acquisition is part of BioNTech's strategy to expand its portfolio in oncology [1] - This move indicates a growing trend in the biotech industry towards consolidation to strengthen capabilities in cancer treatment [1]